Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India-here's what ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. The launch ...

With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Popular anti-diabetes and obesity drug Mounjaro, containing active ingredient tirzepatide, is now available in India in a ...

Researchers have discovered that a drug originally developed for conditions like Alzheimer’s disease, schizophrenia, and ...

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

Eli Lilly India launches Mounjaro, a first-of-its-kind medication for obesity and type 2 diabetes, offering hope for millions ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?